Quince Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sofinnova Capital VIII (“SC VIII”)(5.1%),Sofinnova Partners SAS, a French corporation (“SP SAS”)(5.1%), etc.

SEC announcement · Feb 12 22:04

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Quince Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sofinnova Capital VIII (“SC VIII”)(5.1%),Sofinnova Partners SAS, a French corporation (“SP SAS”)(5.1%), etc.

Risk Disclaimer